Product Description
Benztropine is an anticholinergic agent used predominantly in the symptomatic therapy of Parkinson disease and movement disorders. Benztropine has not been associated with serum enzyme elevations during treatment and has not been linked to cases of clinically apparent acute liver injury. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/BENZTROPINE)
Mechanisms of Action: mAChR Antagonist,DRI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intramuscular
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Canada | Egypt | Hong Kong | Ireland | Korea | New Zealand | Portugal | Singapore | Sri Lanka | Taiwan | Thailand | Turkey | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|